We wish to define the role of certain cell surface molecules in the lytic interaction between lymphocytes and tumor cells. Two important phenomena were previously discovered under this grant: the inverse relationship between MHC antigen expression and NK sensitivity, and the ability of C3 fragments to enhance the cytotoxic effect of NK and some T-cells against certain receptor carrying targets by bridge formation. The exploration of these two phenomena constitute the main focus of the continued project. Our specific projects are as follows: I. INFLUENCE OF THE COMPLEMENT SYSTEM ON LYMPHOCYTE FUNCTIONS I.l. Contribution of NK cell adhesion molecules (leu-CAM), lymphocyte mediated cytotoxicity. I.2. Lymphocyte mediated lysis of target cells equipped with surface reactive antibodies. I.3. Activation of C3 by cells that carry surface associated virus envelope components. I.4. C3 fragment-mediated interaction between activated T-cells and B-cells. II. MHC GENE DEPENDENT CONTROL OF NATURAL TUMOR RESISTANCE II.l. Specific adaptive, natural and lymphokine activated effector mechanisms in MHC transgenic mice. II.2. MHC ligand density in antigen presentation and effector cell triggering. II.3. Natural, specific adaptive and lymphokine induced tumor immunity in the brain. II.4. The influence of host-tumor MHC-interactions on natural resistance against tumors. II.5. Novel immunotherapy strategies: expansion of the NK and LAK repertoire by manipulating of the host bone marrow genome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA025250-12
Application #
3166773
Study Section
Immunobiology Study Section (IMB)
Project Start
1979-07-01
Project End
1992-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Karolinska Institute
Department
Type
DUNS #
350582235
City
Stockholm
State
Country
Sweden
Zip Code
171 7-7
Stuber, G; Dillner, J; Modrow, S et al. (1995) HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 7:653-63
Vegh, Z; Wang, P; Vanky, F et al. (1994) Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas. Cancer Immunol Immunother 38:71-3
Avila-Carino, J; Lewin, N; Yamamoto, K et al. (1994) EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. Int J Cancer 58:678-85
Altiok, A; Di Renzo, L; Altiok, E (1994) Influence of transforming growth factor-beta (TGF-beta) on the immunoglobulin production by EBV-infected B cell cultures. Immunol Lett 43:199-202
Altiok, A; Jadersten, M; Magyarlaki, T et al. (1994) Biphasic effect of transforming growth factor-beta on Epstein-Barr virus-induced activation of human tonsillar B cells. Immunol Lett 40:111-5
Klein, E (1993) Reflections on human tumor immunology. Med Oncol Tumor Pharmacother 10:83-6
Algarra, I; Silva, S; Ljunggren, H G (1993) MHC class I expression on prelymphomatous and lymphomatous B-cells is not inhibited by an E mu-myc transgene. Eur J Cancer 29A:238-41
Vegh, Z; Wang, P; Vanky, F et al. (1993) Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 53:2416-20
Klein, E; Mantovani, A (1993) Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 5:714-8
Kuraya, M; Minarovits, J; Okada, H et al. (1993) HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines. Immunol Lett 37:35-9

Showing the most recent 10 out of 76 publications